Comparison · NCT01591785-2e91b244
Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1. Trial comparisons, record NCT01591785-2e91b244. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01591785-2e91b244
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.332 | 0.668 | wilson | |
| Risk in group 2 | 0.367 | 0.219 | 0.545 | wilson | |
| Risk difference, group 1 minus group 2 | 0.133 | -0.112 | 0.358 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 0.755 | 2.46 | log | |
| Odds ratio, group 1 over group 2 | 1.73 | 0.616 | 4.84 | log | |
| Number needed to treat, for one more participant with the outcome on Retapamulin 1% Ointment than on Placebo Ointment | 7.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Retapamulin 1% Ointment | twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days | 15 | 30 | OG000 |
| Group 2 | Placebo Ointment | twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days | 11 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With PGA of 0 or 1
- Description
- Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)~1 = Almost clear (just perceptible erythema and papulation/infiltration)
- Time frame
- Day 28
- Population
Source ClinicalTrials.gov
Trial
- Title
- Treatment of Staphylococcus Aureus Colonization in Hand Eczema
- NCT number
- NCT01591785
- Phases
- NA
- Conditions
- Hand Eczema, Foot Eczema
- Interventions
- Retapamulin 1% ointment, Placebo
- Lead sponsor
- Gary Goldenberg
- Results first posted
- 2020-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01591785?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01591785-2e91b244